

For Immediate Release
For Further Information Contact:
Andrew Fisher at (301) 608-9292
Email: Afisher@unither.com

**UNITED THERAPEUTICS RECEIVES APPROVAL IN AUSTRALIA FOR
REMODULIN® TO TREAT PULMONARY ARTERIAL HYPERTENSION**

Research Triangle Park, NC and Silver Spring, MD, May 21, 2004: United Therapeutics Corporation (NASDAQ: UTHR) announced today that the Australian Therapeutic Goods Administration has approved Remodulin for the treatment of pulmonary arterial hypertension in patients with NYHA Class III and IV to diminish symptoms associated with exercise. Remodulin is distributed in Australia by Orphan Australia Pty Ltd.

Remodulin is approved in the United States, Canada, Israel and Australia. United Therapeutics is also pursuing marketing authorization in France, Czech Republic, Poland, Hungary, Taiwan and Brazil.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.